IL‐12 minicircle delivery via extracellular vesicles as immunotherapy for bladder cancer

Cell Proliferation, Journal Year: 2024, Volume and Issue: 58(1)

Published: Aug. 28, 2024

Abstract Interleukin‐12 (IL‐12) holds significant potential in cancer therapy; however, its clinical applicability is hindered by dose‐limiting toxicity. Delivery of the IL‐12 gene directly to tumours for constitutive expression a possible strategy enhance effectiveness while minimizing systemic In this study, we investigate red blood cell‐derived extracellular vesicles (RBCEVs) as carrier Il‐12 plasmid delivery. We demonstrate that RBCEVs can be loaded with minicircle encoding and delivered MB49 bladder cells expression. The transgenes from minicircles was significantly higher than parental plasmids. RBCEV‐mediated stimulated immune responses mouse splenocytes. Intratumoral delivery plasmid‐loaded suppressed tumour growth, promoted cell infiltration. conclusion, our study demonstrates promising an effective, safe redosable nucleic acid drug platform IL‐12.

Language: Английский

An evaluation of durvalumab across the spectrum of urothelial carcinoma

Expert Review of Anticancer Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 18, 2024

Urothelial carcinoma is a common malignancy affecting the urinary system, with spectrum of disease encompassing non-muscle invasive, muscle-invasive and metastatic disease. On background almost half century immunogenic management BCG, various immune checkpoint inhibitors, including durvalumab, have now demonstrated clinical efficacy in treatment urothelial carcinoma.

Language: Английский

Muscle‐Derived Bioactive Factors: MyoEVs and Myokines

Cell Proliferation, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 30, 2024

Overview of the functions and applications myokines MyoEVs.

Language: Английский